Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Arteriovenous Malformations of the Brain
NEJM 376:1859-1866, Solomon, R.A. & Connolly, E.S., 2017
Man with Recurrent Paralysis and Cerebral White Matter Lesions
JAMA Neurol 74:599-600, Xiao, F., 2017
Human Immunodeficiency Virus Presenting as Progressive Multifocal Leukoencephalopathy Restricted to the Posterior Fossa
JAMA Neurol 74:597-598, Schubert, R.D. & Richie, M.B., 2017
More to Atherosclerosis Than Stenosis
Stroke 48:e104-e107, Rai, S.,et al, 2017
Outcome of Intracerebral Hemorrhage Associated with Different Oral Anticoagulants
Neurol 88:1693-1700,1686, Wilson, D.,et al, 2017
Lithium-Induced Reversible Pisa Syndrome
Neurol 88:e184, Kumar, N.,et al, 2017
A 45-year-old man with Weakness and Myalgia after Orthopedic Surgery
Neurol 88:e185-e189, Vazquez do Campo, R.,et al, 2017
Pharmacotherapy for Diabetic Peripheral Neuropathy Pain and Quality of Life
Neurol 88:1958-1967, Waldfogel, J.M.,et al, 2017
Anticoagulant and Antiplatelet Use in Seniors with Chronic Subdural Hematoma
Neurol 88:1889-1893, Nathan, S.,et al, 2017
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Lumbar Puncture Test in Normal Pressure Hydrocephalus: Does the Volume of CSF Removed Affect the Response to Tap?
AJNR 38:1456-1460, Thakur, S.K., et al, 2017
TIPIC Syndrome: Beyond the Myth of Carotidynia, a New Distinct Unclassified Entity
AJNR 38:1391-1398, Lecler, A.,et al, 2017
Amyotrophic Lateral Sclerosis
NEJM 377:162-172, Brown, R.H.,et al, 2017
Trial of Tocilizumab in Giant-Cell Arteritis
NEJM 377:317-328,385, Stone, J.H.,et al, 2017
A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
Quality Improvement in Neurology: Inpatient and Emergency Care Quality Measure Set
Neurol 89:730-735, Josephson, S.An.,et al, 2017
Long-Term Antithrombotic Treatment in Intracranial Hemorrhage Survivors with Atrial Fibrillation
Neurol 89:687-696, Korompoki, E.,et al, 2017
Effect of Gluten-Free Diet on Cerebellar MR Spectroscopy in Gluten Ataxia
Neurol 89:705-709, Hadjivassiliou, M.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
NEJM 377:411-414, Goodman, C.W. & Brett, A.S., 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017
CT Angiography ASPECTS Predicts Outcome Much Better Than Noncontrast CT in Patients with Stroke Treated Endovascularly
AJNR 38:1569-1573, Sallustio, F.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Overview of IgG4-related Disease
UptoDate, July, Moutsopoulos,H.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
A Case of Altered Mental Status, Not Otherwise Specified
Neurol 89:e154-e158, Swor, D.E.,et al, 2017
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Diagnostic Challenges in a Young Patient with Hypereosinophilia
Neurol 89:e159-e165, Ortiz, J.G.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Zolpidem for the Treatment of Neurologic Disorders
JAMA Neurol 74:1130-1139, Bomalaski, M.N.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Neuroimaging Changes in Menkes Disease, Part 1
AJNR 38:1850-1857, Manara, R.,et al, 2017
Intrathecal 2-hydroxypropyl-�-cyclodextrin Decreases Neurological Disease Progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial
Lancet 390:1758-1768, Ory, D.S.,et al, 2017
Short-Course Radiation Plus Temozolomide in Elderly Patients with Glioblastoma
NEJM 376:1027-1037, Perry, J.R.,et al, 2017
Clinicopathologic Conference, Primary Adrenal Insufficiency (Addisons Disease)
NEJM 376:1159-1167, Case 9-2017, 2017
Management of Sciatica
NEJM 376:1175-1177, Ramaswami, Ramya, 2017